CareMax, Inc. (CMAX)
NASDAQ: CMAX · IEX Real-Time Price · USD
2.930
+0.050 (1.74%)
May 31, 2024, 4:00 PM EDT - Market closed
CareMax Stock Forecast
CMAX's stock price has decreased by -96.29% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CareMax stock have an average target of 33.2, with a low estimate of 6.40 and a high estimate of 60. The average target predicts an increase of 1,033.11% from the current stock price of 2.93.
Analyst Consensus: Hold
* Price targets were last updated on Apr 1, 2024.
Analyst Ratings
The average analyst rating for CareMax stock from 2 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Maintains $7 → $6.4 | Hold | Maintains | $7 → $6.4 | +118.43% | Apr 1, 2024 |
| UBS | UBS | Strong Buy → Hold Downgrades $150 → $30 | Strong Buy → Hold | Downgrades | $150 → $30 | +923.89% | Nov 17, 2023 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $60 | Buy → Hold | Downgrades | $60 | +1,947.78% | Nov 10, 2023 |
| UBS | UBS | Strong Buy Maintains $300 → $180 | Strong Buy | Maintains | $300 → $180 | +6,043.34% | Jan 6, 2023 |
| Truist Securities | Truist Securities | Hold Initiates $225 | Hold | Initiates | $225 | +7,579.18% | Sep 7, 2022 |
Financial Forecast
Revenue This Year
916.65M
from 751.10M
Increased by 22.04%
Revenue Next Year
942.62M
from 916.65M
Increased by 2.83%
EPS This Year
-33.78
from -183.31
EPS Next Year
-23.62
from -33.78
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 945.0M | 1.0B | 1.2B | 1.5B | 1.8B |
| Avg | 916.7M | 942.6M | 1.1B | 1.4B | 1.8B |
| Low | 879.4M | 833.0M | 1.1B | 1.4B | 1.7B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 25.8% | 14.3% | 25.3% | 28.0% | 27.0% |
| Avg | 22.0% | 2.8% | 21.8% | 24.3% | 23.4% |
| Low | 17.1% | -9.1% | 17.0% | 19.4% | 18.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -34.78 | -24.32 | -11.58 |
| Avg | -33.78 | -23.62 | -11.25 |
| Low | -32.46 | -22.70 | -10.81 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.